KURA
Wall Street’s been busy with Kura
Kura Oncology woke up to a very familiar kind of headline: brokers still like the story, even if the latest quarter was a bit of a faceplant. MarketBeat says 13 analysts now average out to a “Moderate Buy” on the stock, with 10 buy ratings, 2 holds, and 1 sell. The average 12-month price target is $26.38.
The good news: analysts still see upside
That’s the part investors usually zoom in on. A consensus target north of where a beaten-down biotech has been trading can act like a tiny morale boost — especially when the pipeline is doing the heavy lifting and the market is trying to decide whether to believe the science or the spreadsheet.
There’s also a fresh note from Lake Street Capital, which started coverage with a buy rating and a $23 price target. UBS, meanwhile, kept its buy call but trimmed its target to $15 from $16. Translation: the Street is not exactly singing in perfect harmony, but the choir is still leaning bullish.
The not-so-great part: the earnings snapshot was messy
The same report also reminds you that Kura’s last quarter was rough. The company posted $(0.92) EPS versus expectations for $(0.72), and revenue came in at $17.34 million versus $34.71 million expected. For a clinical-stage biotech, that’s less about “missed by a hair” and more “the runway math got a little spicy.”
Big picture: the analyst setup says Kura still has believers, but the stock will probably keep living and dying by clinical updates, not consensus price targets. In biotech, the pipeline is the plot twist — and the Street is betting there’s another act coming.